Time is now
Posted: Sun Jul 06, 2025 10:42 pm
We’ll soon see if this is a Zombie company, as the stock price is portending, or not. Period.
This Q’s earnings will show growth, or not. If we start to see growth, then it’s just a hop skip and a jump to the MF Phase III findings, which to near certainty/obviousness will show much longer life expectancy than BAT, since the study has taken forever to get to the data readout specified by the trial design.
But if the MDS launch is truly stuck in the water and a bust, then who cares.
I happen to think there will be Revenue growth shown in this past quarter. I don’t think the institutional holding % would be so high if it wasn’t. They would know, they spend a lot of money protecting their investments - they have a read on the market I am more than sure. To boot, the drop in retail % and capitulation we have witnessed among many long time believers / holders, does stink but probably par for the course in this type of investment…
The wait has been truly tiresome, and anyone still enthusiastic drinks too much coffee or something. But (but but but) the drug works, is showing benefit in patients, should have increased uptake in clinical, and value should take be discovered for the company, in due course…
This Q’s earnings will show growth, or not. If we start to see growth, then it’s just a hop skip and a jump to the MF Phase III findings, which to near certainty/obviousness will show much longer life expectancy than BAT, since the study has taken forever to get to the data readout specified by the trial design.
But if the MDS launch is truly stuck in the water and a bust, then who cares.
I happen to think there will be Revenue growth shown in this past quarter. I don’t think the institutional holding % would be so high if it wasn’t. They would know, they spend a lot of money protecting their investments - they have a read on the market I am more than sure. To boot, the drop in retail % and capitulation we have witnessed among many long time believers / holders, does stink but probably par for the course in this type of investment…
The wait has been truly tiresome, and anyone still enthusiastic drinks too much coffee or something. But (but but but) the drug works, is showing benefit in patients, should have increased uptake in clinical, and value should take be discovered for the company, in due course…